Share
656 Posts.
lightbulb Created with Sketch. 285
clock Created with Sketch. 26/09/20
22:49
Share
Originally posted by Exalted:
↑
I think to me the biggest glaring mispricing issue is not to do with the probability of successful results.where we are heading into the trial and its results. DXB holders sitting pretty at a 75c SP and 150M MC were hoping that successful Phase 2B results for their rare kidney disease drug would rocket them to 250M MC and beyond. BOT holders in the 25-29c range at 200-250M MC were hoping that their Phase 2B Acne results would rocket them to 40-50c. Phase 2B trial concurrently with two preclinical studies for two different drugs, making three in total running at the same time with $12.5M cash and 50M MC. Such a company without any actual successful Phase 2B result should already be trading at multiples of its current valuation. A successful Phase 2B should add even further market cap on on top of that. So tldr, IHL should re-rate to at least double if not higher than where it is right now before any actual results come through.
Expand
I dont see that at ramping either, youre stating facts and i agree with everything youve stated. on oil sales alone i think we deserve a rerate to the mid teens! I think bot like others have stated really shook some investors up and they possibly lost some confidence hence why were still at these levels. Market will up to this gem soon enough
